查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844072

幽門螺旋桿菌診斷市場按檢測類型、產品類型、最終用戶和技術分類－2025-2032年全球預測

Helicobacter Pylori Diagnostics Market by Test Type, Product Type, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，幽門螺旋桿菌診斷市場將成長至 17.7078 億美元，複合年成長率為 10.06%。

關鍵市場統計數據
基準年 2024 8.2228億美元
預計年份：2025年 9.0604億美元
預測年份 2032 17.7078億美元
複合年成長率 (%) 10.06%

幽門螺旋桿菌診斷的權威概述重點介紹了臨床意義、診斷方法、患者診療路徑以及在醫療保健機構中準確檢測的策略重要性。

幽門螺旋桿菌是胃腸病學領域的焦點，因為它已被證實是慢性胃炎、消化性潰瘍和胃癌的危險因子。因此，準確及時的診斷至關重要，它影響著治療方法的選擇、根除監測以及更廣泛的公共衛生工作。目前有侵入性和非侵入性兩種幽門螺旋桿菌感染診斷方法，每種方法在敏感性、特異性、週轉時間和資源消耗方面各有優劣。

臨床實驗室和醫護人員必須考慮檢測的性能特徵，並結合患者的臨床表現、先前治療史以及檢測結果的預期用途（例如，初步診斷、確認根除或抗藥性監測）。雖然分子檢測近年來已與傳統的組織學和培養檢測相結合，但非侵入性抗原檢測和呼吸檢測仍然是門診病人評估的主要手段。這些方法應用於各種醫療機構，從基層醫療診所到大型醫院系統，每個機構都有其獨特的營運限制和採購優先事項。

隨著診斷技術的不斷發展，實驗室工作流程、臨床醫生偏好和支付方政策之間的相互作用變得日益重要。有效的診斷策略需要統一的檢體採集通訊協定、品管和臨床醫生培訓，以確保選擇和解讀合適的檢測方法。此外，診斷選擇直接影響抗菌藥物管理工作和後續臨床結局，因此亟需建立臨床上可靠且易於操作的診斷路徑。

技術、營運和數位化變革正在改變幽門螺旋桿菌的診斷方式，並影響臨床決策和市場動態。

由於分子技術的進步、照護現場設備的微型化以及非侵入性檢測能力的提升，幽門螺旋桿菌的診斷格局正在迅速轉變。分子平台正從集中式實驗室PCR系統擴展到床邊等溫PCR方法和即時PCR儀，這些儀器能夠同時提供幽門螺旋桿菌的檢測和抗菌藥物抗藥性標記。同時，增強型免疫測量和高性能糞便抗原檢測也在不斷改進非侵入性篩檢和治療後確認方法。

同時，內視鏡技術和影像增強演算法的進步提高了視覺檢測能力，並實現了標靶切片檢查，從而提高了診斷率。人工智慧工具正開始輔助病灶識別和手術流程標準化，加上染色和組織學技術的改進，在臨床需要時，侵入性診斷的作用日益凸顯。這些轉變將推動更精準的治療決策，並更好地契合抗菌藥物管理的目標。

在營運層面，去中心化正在重塑採購和服務交付模式。即時偵測加快了結果出爐速度，並可整合到門診工作流程中。數位醫療、遠端醫療和實驗室互聯互通的整合也支持更順暢的結果共用和後續跟進，從而提高根除通訊協定的依從性。這些技術和營運方面的轉變創造了新的商業性和臨床機遇，同時也帶來了驗證、品質保證和報銷方面的新挑戰。

評估2025年美國關稅如何改變了幽門螺旋桿菌診斷的供應鏈、生產決策和籌資策略

美國將於2025年實施關稅，將對診斷生態系統產生多方面的影響，包括組件採購、定價策略和供應鏈架構。關稅主導的成本壓力迫使進口耗材、試劑和分析儀組件的價格上漲，促使許多製造商和臨床實驗室重新評估其供應商關係和庫存管理實踐。因此，採購團隊正在延長前置作業時間並增加緩衝庫存，以降低潛在的供應中斷風險。

在產品層面，關稅促使大量耗材和檢測試劑套件在本地生產或外包。一些診斷公司已採取措施應對，例如認證更多國內製造外包或將組裝遷至受貿易壁壘影響較小的地區。雖然這些策略舉措旨在保障供應的連續性並降低關稅波動帶來的風險，但它們需要對品質系統、監管許可和供應商審核進行投資。

醫療機構面臨著相互矛盾的壓力：既要維持臨床檢驗的檢測流程，也要應對預算限制。實驗室和醫院正在仔細評估分析儀的單次檢測成本和總擁有成本，權衡資本投資與試劑依賴性以及服務合約條款。規模較小的診所和門診中心正在考慮透過集團採購組織和長期供應協議進行集中採購，以確保獲得必要的診斷服務。

隨著對國產檢測產品來源和可追溯性的要求日益提高，監管合規和文件記錄變得癒合重要。優先考慮供應鏈多元化的供應商強調透明的品管和加快監管申報流程，從而縮短替代產品的上市時間。總體而言，關稅環境正在推動製造、採購和臨床應用路徑的結構性變革，迫使相關人員在提升韌性投資和控制短期營運成本之間尋求平衡。

基於細分市場的洞察，揭示了檢測類型、產品類型、最終用戶需求和技術類別在塑造診斷應用和投資重點方面的交匯點。

透過精細化的市場細分，我們可以洞察臨床需求與技術能力的交會點，從而找到最具回報的策略投資方向。無論檢測類型如何，組織檢測仍然是侵入性診斷流程的基石，通常採用蘇木精-伊紅染色和用於病原體可視化的專用染色劑。分子檢測技術正在不斷發展，從用於快速床邊檢測的等溫擴增，到用於高靈敏度檢測的傳統聚合酵素鏈鎖反應，再到用於定量和抗藥性標記鑑定的即時PCR。快速尿素酶檢測在內鏡實驗室中仍發揮效用，目前常用的檢測方法包括Clo檢測和PyloriTek檢測，這些檢測方法優先考慮速度和易於判讀的特性。血清學檢測在流行病學研究和特定臨床情況下仍發揮作用，但作為治療後確認的首選方法，其主要手段是酵素結合免疫吸附試驗和橫向流動化驗。透過酵素免疫分析法和側向流動免疫檢測進行糞便抗原檢測，支持非侵入性診斷和根除檢驗，尿素呼氣試驗（有 13C 和 14C 變體）仍然是一種高度準確的非侵入性選擇，常用於基層醫療和專科機構。

在評估產品類型時，由於套件、試劑和試紙的持續需求，耗材在常規檢測中佔據主導地位。試劑套件包括用於分子檢測的PCR試劑套件、專為特定操作客製化的快速尿素酶檢測試劑盒、針對批量檢測最佳化的血清檢測套組、適用於門診檢體處理的糞便抗原檢測套組以及與呼氣分析儀兼容的尿素呼吸檢測套件。分析設備包括呼氣檢測套組、免疫檢測分析儀和PCR儀，其通量、自動化程度和連接方式各不相同。內視鏡系統對於侵入性診斷和治療性介入至關重要，因此推動了對整合影像和切片檢查功能的需求。

終端使用者引入的操作細節會影響產品偏好和購買行為。包括社區健康中心和門診診所在內的行動醫療中心優先考慮快速、易於操作的非侵入性檢測和耐用的即時檢測解決方案。無論是初級診所還是專科診所，都需要在成本和臨床療效之間取得平衡，以支持常規篩檢和追蹤。診斷實驗室分為商業實驗室和參考實驗室，它們傾向於使用高通量分子儀器和自動化免疫檢測平台，以實現可擴展的檢測和多重分析能力。包括大型三級醫院和小型區域醫療機構在內的醫院，需要將強大的內視鏡功能與一系列分析儀和耗材結合，以支援住院和門診工作流程。

技術領域區分了侵入性方法（例如培養、組織學和快速尿素酶試驗）和無創技術（例如抗原檢測、呼吸檢測、分子檢測和血清學檢測）。值得注意的是，呼吸檢測的定義涵蓋了糞便抗原檢測和尿素呼吸檢測，並結合了它們在臨床應用中的具體情況，這反映了非侵入性樣本類型和分析平台在實際操作部署中的重疊性。這種細緻的分類凸顯了供應商需要根據每個最終用戶群和檢測環境的獨特工作流程需求來客製化產品設計和商業化策略。

美洲、歐洲、中東和非洲以及亞太地區不同的診斷動態揭示了檢測策略的採納、基礎設施和政策方面存在的問題。

區域動態對診斷選擇、報銷和應用路徑有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出清晰的模式。在美洲，成熟的實驗室網路和先進的報銷機制有利於高靈敏度分子檢測和整合分析儀平台的應用。中心實驗室和參考檢測服務支援複雜的分子檢測流程，而門診和日間診療中心則擴大採用即時檢測（POC​​）解決方案以縮短治療時間。該地區也日益重視抗菌藥物管理計畫和治療後確認方案，這些因素正在影響檢測選擇。

歐洲、中東和非洲的市場呈現異質性，監管環境各異，醫療基礎設施也不斷變化。一些國家正在迅速推廣非侵入性檢測和呼氣分析儀，而其他國家則由於臨床醫生的偏好和資源限制，仍然依賴傳統的組織檢測和內視鏡診斷。這些市場的報銷政策和國家指南可能會顯著改變商業性格局，因此需要區域性的證據收集和相關人員的參與才能促進技術的普及應用。

亞太地區的情況十分複雜，某些次區域疾病高發，國內製造業產能不斷成長，技術應用也日新月異。糞便抗原檢測和尿素呼氣試驗等非侵入性診斷方法在基層醫療中尤其重要，因此在分子平台和耗材本地化生產方面都投入了大量資金。私人醫療保健的成長和診斷實驗室網路的擴張正在加速自動化分析儀和多重分子檢測技術的應用，而一些國家的政府公共衛生工作則優先考慮篩檢和消除項目，這影響了採購和實施策略。

從競爭對手觀點分析幽門螺旋桿菌診斷領域的競爭定位，並著重於產品效能、夥伴關係模式、供應鏈韌性和臨床證據策略。

幽門螺旋桿菌診斷領域的競爭格局有利於那些能夠將強大的檢測性能、可靠的供應鏈、監管專業知識和清晰的臨床價值命題主張相結合的公司。成熟的儀器製造商憑藉裝置量、服務網路和用於結果管理的整合軟體保持優勢，而敏捷的分子生物學公司則憑藉快速的檢測開發週期和抗藥性檢測能力脫穎而出。能夠證明其檢測性能在不同檢體類型中具有可重複性，並投資於品質認證的套件和試劑供應商，更有可能贏得與商業實驗室和醫院實驗室的長期合約。

隨著企業尋求提供能夠簡化實驗室客戶實施流程的端到端解決方案，儀器供應商與偵測開發人員之間的策略夥伴關係和共同開發契約正變得越來越普遍。能夠在滿足嚴格品質標準的同時擴大生產規模的契約製造製造商是寶貴的合作夥伴，尤其是在關稅壓力和供應鏈韌性面臨挑戰的時期。此外，能夠提供全面的培訓、技術支援以及將檢測結果整合到電子健康記錄中的連接解決方案的公司也越來越受到機構買家的青睞。

專注於多重檢測、抗藥性基因分型和簡化樣本到結果工作流程的創新產品線正日益受到臨床醫生和採購團隊的青睞。投資於嚴謹的臨床檢驗研究並與關鍵意見領袖合作以產生真實世界證據的公司將鞏固其市場地位。最後，積極管理監管申報並在關鍵地區證明合規性的公司將減少實施阻力並加速商業化部署。

為診斷試劑生產商、實驗室和醫療系統提供切實可行的策略建議，以加速幽門螺旋桿菌檢測的推廣應用、提高應對能力並最大限度地發揮其臨床價值。

產業領導者應考慮採取一系列切實可行的措施，以充分利用新興的診斷趨勢，同時降低營運風險。首先，應優先投資於非侵入性分子檢測和高性能抗原檢測，以簡化工作流程並減少對侵入性操作的依賴，同時確保這些檢測方法已通過驗證，可用於其預期的臨床用途。其次，應實現供應鏈多元化，增加供應商數量，並評估近岸外包和區域製造夥伴關係，以降低貿易中斷帶來的風險並縮短前置作業時間。

第三，我們將制定一項支付方和醫療系統參與策略，闡明準確診斷的臨床和經濟價值，包括檢測在減少不必要的抗生素使用和預防後續併發症的作用。第四，我們將開發整合解決方案，將分析儀、耗材套件和數位連接結合，以增強數據流、實現品管並支援臨床醫生的決策。第五，我們將投資於抗菌藥物抗藥性檢測能力和相應的臨床醫生培訓，以加強抗菌藥物管理並提供可操作的治療指南。

第六，我們將與內視鏡系統供應商和實驗室自動化合作夥伴建立策略夥伴關係，以建構與醫療機構工作流程相契合的綜合診斷路徑。第七，我們將積極拓展不同地區的市場，重點關注監管合規性，並透過多中心檢驗研究快速取得證據。最後，我們將推出靈活的商業模式，例如試劑租賃、訂閱定價和結果掛鉤契約，以滿足買方偏好，並在引進週期內與客戶共用風險。

一項綜合性的混合方法研究途徑，結合專家訪談、工作流程分析、監管審查和技術評估，檢驗診斷見解和影響。

本分析所依據的研究採用了混合方法，將一手定性研究成果與二手證據綜合和技術評估相結合。一手研究包括對臨床醫生、實驗室主任、採購負責人和行業高管進行結構化訪談，以了解實際的診斷工作流程、採購理由和未滿足的需求。此外，還進行了現場考察和工作流程圖繪製，以更深入地了解檢體處理、結果報告以及照護現場和檢測系統整合等環節。

二級研究涵蓋了同行評審文獻、臨床指南、監管文件和技術產品規格，以檢驗檢測性能特徵並比較不同技術平台。技術評估包括分析靈敏度、特異性、週轉時間、通量和操作規模。此外，還審查了主要司法管轄區的監管路徑，以確定證據要求和核准時間表。

本調查方法採用資料三角測量法來調和一手資訊和二手資訊之間的差異，並確保結論的穩健性。在條件允許的情況下，我們使用臨床檢驗研究和真實世界性能數據來評估診斷效用及其對不同終端使用者環境的適用性。本研究方法也承認其局限性，例如測試實施中可能存在的差異以及區域指南的不同，並強調研究結果旨在支持策略決策，而非提供強制性的臨床指導。

總結而言，診斷創新、營運韌性和臨床管理之間的策略性融合將塑造幽門螺旋桿菌檢測的未來。

幽門螺旋桿菌診斷正處於曲折點，分子技術的進步、非侵入性檢測方法的改進以及臨床路徑的不斷完善，使得患者管理更加精準。整個生態系統中的相關人員——包括製造商、實驗室、臨床醫生和醫療保健系統——必須適應技術進步，同時應對供應鏈的複雜性和不斷變化的報銷機制。產品設計、證據產生和最終用戶需求之間的策略性協調，對於充分發揮下一代診斷技術的臨床和商業性潛力至關重要。

未來的成功取決於能否提供臨床相關且運作永續的解決方案，這些方案需與診療路徑相整合，並支援抗菌藥物管理。透過優先考慮採購的韌性、投資於經臨床檢驗的技術，並以清晰的提案主張與支付方和醫療服務提供者建立聯繫，各機構可以改善患者預後並獲得競爭優勢。不斷變化的市場環境為那些將卓越技術能力與切實可行的商業化策略相結合，並能應對區域和終端用戶差異的公司提供了巨大的機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過整合人工智慧增強型內視鏡成像平台，實現幽門螺旋桿菌的即時檢測和診斷。
  • 擴大照護現場診斷檢測規模，用於快速幽門螺旋桿菌抗生素抗藥性分析
  • 在基層醫療中擴大採用非侵入性的 13C-尿素呼吸檢測進行幽門螺旋桿菌早期篩檢
  • 開發一種結合幽門螺旋桿菌毒力因子檢測和生物標記分析的多重血清學檢測方法
  • 數位健康平台的出現以及幽門螺旋桿菌診斷結果在患者管理中的整合
  • 加強診斷設備製造商與胃腸病診所之間的合作，以簡化幽門螺旋桿菌檢測流程。
  • 監管部門的核准加速了次世代定序在幽門螺旋桿菌菌株鑑定中的應用
  • 在資源匱乏的環境中，對糞便抗原免疫檢測的需求日益成長，這有助於幽門螺旋桿菌的診斷。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 幽門螺旋桿菌診斷市場（依檢測類型分類）

  • 組織學
    • 蘇木精-伊紅染色
    • 特殊染色
  • 分子檢測
    • 等溫擴增
    • 聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應
  • 快速尿素酶試驗
    • 黑檢
    • Pyrolitec 測試
  • 血清學檢測
    • 酵素結合免疫吸附試驗
    • 橫向流動化驗
  • 糞便抗原檢測
    • 酵素免疫分析法
    • 側向流動免疫檢測
  • 尿素呼氣試驗
    • 13C-尿素呼氣試驗
    • 14C-尿素呼氣試驗

9. 幽門螺旋桿菌診斷市場（依產品類型分類）

  • 消耗品
    • 套件
      • PCR試劑套件
      • 快速尿素酶檢測套組
      • 血清檢測套組
      • 糞便抗原檢測套組
      • 尿素呼吸檢測套件
    • 試劑
    • 測試條
  • 裝置
    • 分析器
      • 呼吸檢測分析儀
      • 免疫檢測分析儀
      • PCR裝置
    • 內視鏡系統

第10章 幽門螺旋桿菌診斷市場（依最終用戶分類）

  • 門診治療中心
    • 社區健康中心
    • 門診部
  • 診所
    • 基層醫療診所
    • 專科診所
  • 診斷實驗室
    • 商業實驗室
    • 參考實驗室
  • 醫院
    • 大型醫院
    • 小型醫院

第11章 幽門螺旋桿菌診斷市場（依技術分類）

  • 侵入性
    • 文化
    • 組織學
    • 快速尿素酶試驗
  • 非侵入性
    • 抗原檢測
    • 呼吸檢測
      • 糞便抗原檢測
      • 尿素呼吸檢測
    • 分子
    • 血清

第12章 幽門螺旋桿菌診斷市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 幽門螺旋桿菌診斷市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國幽門螺旋桿菌診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Danaher Corporation
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
    • Fujirebio Inc.
    • Sekisui Medical Co., Ltd.
Product Code: MRR-CA17E905E785

The Helicobacter Pylori Diagnostics Market is projected to grow by USD 1,770.78 million at a CAGR of 10.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 822.28 million
Estimated Year [2025] USD 906.04 million
Forecast Year [2032] USD 1,770.78 million
CAGR (%) 10.06%

A definitive overview of Helicobacter pylori diagnostics highlighting clinical implications, diagnostic modalities, patient pathways, and the strategic importance of accurate testing across care settings

Helicobacter pylori remains a central concern in gastrointestinal medicine due to its established role in chronic gastritis, peptic ulcer disease, and as a risk factor for gastric malignancy. Accurate, timely diagnosis is therefore a clinical imperative that affects therapy selection, eradication monitoring, and broader public health efforts. Diagnostics for H. pylori span invasive and noninvasive approaches, each offering distinct trade-offs between sensitivity, specificity, turnaround time, and resource intensity.

Clinical laboratories and care providers must consider test performance characteristics in the context of patient presentation, prior treatment history, and the intended use of results-whether for initial diagnosis, confirmation of eradication, or surveillance for resistance. Recent years have seen the integration of molecular methods alongside traditional histology and culture, while noninvasive antigen and breath tests remain central to outpatient evaluation. These modalities are deployed across varied settings from primary care clinics to large hospital systems, with each setting imposing unique operational constraints and procurement priorities.

As diagnostics evolve, the interplay between laboratory workflows, clinician preferences, and payer policies becomes increasingly consequential. Effective diagnostic strategies require harmonization of specimen collection protocols, quality controls, and clinician education to ensure appropriate test selection and interpretation. Furthermore, diagnostic choice directly influences antibiotic stewardship efforts and downstream clinical outcomes, reinforcing the need for diagnostic pathways that are both clinically robust and operationally feasible.

Transformative technological, operational, and digital shifts reshaping Helicobacter pylori diagnostics with implications for clinical decision making and market dynamics

The diagnostic landscape for Helicobacter pylori is undergoing a rapid transformation driven by advances in molecular technologies, point-of-care instrument miniaturization, and improved noninvasive testing performance. Molecular platforms are expanding from centralized laboratory PCR systems to near-patient isothermal approaches and real-time PCR instruments that provide both detection and antimicrobial resistance markers. At the same time, enhanced immunoassays and high-performance stool antigen tests are refining noninvasive screening and post-treatment confirmation.

Concurrently, endoscopy technology and image-enhancement algorithms are improving visual detection and enabling targeted biopsies that increase diagnostic yield. Artificial intelligence tools are beginning to support lesion recognition and procedural standardization, which, together with enhanced staining and histological techniques, strengthen the role of invasive diagnostics where clinically indicated. These shifts facilitate more precise therapeutic decisions and better alignment with stewardship goals.

Operationally, the movement toward decentralization is reshaping procurement and service delivery. Point-of-care tests reduce time-to-result and can be integrated into ambulatory workflows, while analyzer equipment continues to add throughput and multiplexing capabilities. The convergence of digital health, telemedicine, and laboratory connectivity also supports more seamless result sharing and follow-up, thereby improving adherence to eradication protocols. Taken together, these technological and operational shifts create new commercial and clinical opportunities while raising fresh challenges around validation, quality assurance, and reimbursement.

Assessing how the 2025 United States tariff measures have reshaped supply chains, manufacturing decisions, and procurement strategies across Helicobacter pylori diagnostics

The introduction of United States tariffs in 2025 has produced multifaceted impacts on the diagnostics ecosystem, influencing component sourcing, pricing strategies, and supply chain architecture. Tariff-driven cost pressures on imported consumables, reagents, and analyzer components have led many manufacturers and clinical laboratories to re-evaluate vendor relationships and inventory management practices. In turn, procurement teams have adopted longer lead times and increased buffer stocks to mitigate potential supply disruptions, which affects working capital and operational logistics.

At the product level, tariffs have incentivized local manufacturing or nearshoring initiatives for high-volume consumables and assay kits. Some diagnostic firms responded by qualifying additional domestic contract manufacturers or by relocating assembly lines to jurisdictions less affected by trade barriers. These strategic moves are intended to protect continuity of supply and to reduce exposure to tariff volatility, though they require investment in quality systems, regulatory permits, and supplier audits.

Healthcare providers face competing pressures: the need to maintain clinically validated testing algorithms while managing budgetary constraints. Laboratories and hospitals have scrutinized cost-per-test and total cost of ownership for analyzers, weighing capital acquisition against reagent dependency and service agreement terms. Smaller clinics and ambulatory centers, often with tighter margins, have had to consider consolidated purchasing through group purchasing organizations or long-term supply agreements to preserve access to essential diagnostics.

Regulatory compliance and documentation have become more salient as provenance and traceability requirements increase for domestically sourced assays. Suppliers prioritizing diversified supply chains have also emphasized transparent quality controls and rapid regulatory filings to shorten time-to-market for alternatives. Overall, the tariff environment has catalyzed structural changes across manufacturing, procurement, and clinical adoption pathways, prompting stakeholders to balance resilience investments against near-term operational costs.

Segment-driven insights revealing where test types, product formats, end-user needs, and technology categories converge to shape diagnostic adoption and investment priorities

Insights derived from granular segmentation illuminate where clinical demand converges with technological capability and where strategic investments will yield the greatest returns. Across test types, histology remains a cornerstone in invasive diagnostic workflows and is typically executed with hematoxylin and eosin staining complemented by special stains to enhance organism visualization. Molecular testing has broadened its footprint, with isothermal amplification providing rapid near-patient detection, conventional polymerase chain reaction used in reference laboratories for high-sensitivity assays, and real-time PCR offering quantitation and resistance marker identification. Rapid urease tests retain utility in endoscopy suites and are commonly available as Clo test formats and PyloriTek test variants that prioritize speed and ease of interpretation. Serology continues to play a role in epidemiologic studies and specific clinical contexts through enzyme-linked immunosorbent assays and lateral flow assays, although it is less favored for post-treatment confirmation. Stool antigen testing, delivered via enzyme immunoassays or lateral flow immunoassays, supports noninvasive diagnosis and eradication verification, while urea breath tests, available as 13C and 14C variants, remain a highly accurate noninvasive option often used in primary care and specialist settings.

When evaluating product types, consumables dominate routine testing due to the continual need for kits, reagents, and test strips. Kits span PCR kits for molecular detection, rapid urease test kits tailored for procedural use, serology kits optimized for batch testing, stool antigen test kits suitable for outpatient specimen processing, and urea breath test kits designed for breath analyzer compatibility. Instruments encompass analyzer equipment and endoscopy systems, with analyzer categories including breath test analyzers, immunoassay analyzers, and PCR instruments that vary by throughput, automation level, and connectivity. Endoscopy systems remain critical for invasive diagnostics and therapeutic interventions, driving demand for integrated imaging and biopsy capabilities.

End users introduce operational nuance that shapes product preference and purchasing behavior. Ambulatory care centers, comprised of community health centers and outpatient clinics, prioritize rapid, easy-to-administer noninvasive tests and durable point-of-care solutions. Clinics, whether primary care or specialty-focused, balance cost and clinical performance to support routine screening and follow-up. Diagnostic laboratories, split between commercial and reference laboratories, favor high-throughput molecular instruments and automated immunoassay platforms that enable scalable testing and multiplex capacity. Hospitals, including both large tertiary centers and smaller community facilities, require a hybrid mix: robust endoscopy capabilities for invasive diagnosis and a portfolio of analyzers and consumables that support inpatient and outpatient workflows.

Technology segmentation distinguishes invasive modalities such as culture, histology, and rapid urease testing from noninvasive approaches like antigen testing, breath testing, molecular assays, and serology. Notably, breath testing is contextualized to include both stool antigen test approaches and urea breath tests in applied clinical pathways, reflecting how noninvasive sample types and analytic platforms can overlap in operational deployment. This nuanced segmentation underscores the need for vendors to align product design and commercialization strategies with the distinct workflow requirements of each end-user segment and testing environment.

Regionally differentiated diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific revealing adoption, infrastructure, and policy implications for testing strategies

Regional dynamics exert a powerful influence on diagnostic choice, reimbursement, and adoption pathways, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, mature laboratory networks and advanced reimbursement frameworks favor the uptake of high-sensitivity molecular assays and integrated analyzer platforms. Centralized laboratories and reference testing services support complex molecular workflows, while ambulatory care and outpatient clinics increasingly adopt point-of-care solutions to shorten time-to-treatment. This region also emphasizes antimicrobial stewardship programs and post-treatment confirmation protocols that influence test selection.

In Europe, the Middle East & Africa, regulatory diversity and variable healthcare infrastructure create a heterogeneous marketplace. Some countries demonstrate rapid adoption of noninvasive testing and breath analyzers supported by public health screening initiatives, whereas others rely on traditional histology and endoscopy-based diagnostics due to clinician preference or resource constraints. Reimbursement policies and national guidelines in these markets can materially alter the commercial landscape, necessitating localized evidence generation and stakeholder engagement to achieve adoption.

The Asia-Pacific region presents a complex mix of high disease prevalence in certain subregions, growing domestic manufacturing capabilities, and rapid technological adoption. Noninvasive diagnostics such as stool antigen tests and urea breath tests are particularly valuable in primary care settings, and there is notable investment in both molecular platforms and local production of consumables. Private healthcare growth and expanding diagnostic laboratory networks are accelerating the adoption of automated analyzers and multiplex molecular assays, while governmental public health efforts in some countries prioritize screening and eradication programs that influence procurement and implementation strategies.

Company-level perspectives emphasizing product performance, partnership models, supply chain resilience, and clinical evidence strategies that determine competitive positioning in H pylori diagnostics

Competitive dynamics in the diagnostics landscape favor companies that combine robust assay performance with reliable supply chains, regulatory expertise, and clear clinical value propositions. Established instrument manufacturers maintain an advantage through installed base, service networks, and integrated software for result management, while agile molecular firms differentiate via rapid assay development cycles and resistance detection capabilities. Kit and reagent suppliers that can demonstrate reproducible performance across specimen types and that invest in quality certification are positioned to win long-term contracts with commercial and hospital laboratories.

Strategic partnerships and co-development agreements between instrument vendors and assay developers are increasingly common as firms seek to offer end-to-end solutions that simplify adoption for laboratory customers. Contract manufacturing organizations that can scale production while meeting stringent quality standards are valuable partners, particularly in contexts where tariff pressures and supply chain resilience are priorities. Additionally, companies that provide comprehensive training, technical support, and connectivity solutions to integrate test results into electronic health records gain traction with institutional purchasers.

Innovation pipelines focused on multiplexing, resistance genotyping, and simplified sample-to-answer workflows attract attention from both clinicians and procurement teams. Firms that invest in robust clinical validation studies and that engage with key opinion leaders to generate real-world evidence strengthen their market positioning. Finally, organizations that proactively manage regulatory filings and demonstrate compliance across major regions reduce adoption friction and accelerate commercial rollouts.

Actionable strategic recommendations for diagnostic manufacturers, laboratories, and health systems to accelerate adoption, improve resilience, and maximize clinical value of H pylori testing

Industry leaders should consider a set of pragmatic actions to capitalize on emerging diagnostic trends while mitigating operational risk. First, prioritize investment in noninvasive molecular and high-performance antigen assays that streamline workflows and reduce reliance on invasive procedures, while ensuring assays are validated for intended clinical uses. Second, diversify supply chains by qualifying additional suppliers and by evaluating nearshoring or regional manufacturing partnerships to reduce exposure to trade-related disruptions and to improve lead times.

Third, build payer and health system engagement strategies that articulate the clinical and economic value of accurate diagnostics, including the role of testing in reducing unnecessary antibiotic use and in preventing downstream complications. Fourth, develop integrated solutions that pair analyzers with consumable kits and digital connectivity to enhance data flow, enable quality controls, and support clinician decision making. Fifth, invest in antimicrobial resistance testing capabilities and corresponding clinician education to reinforce stewardship and to provide actionable therapeutic guidance.

Sixth, pursue strategic collaborations with endoscopy system providers and laboratory automation partners to create comprehensive diagnostic pathways that align with institutional workflows. Seventh, emphasize regulatory preparedness and rapid evidence generation through multicenter validation studies to facilitate market entry across diverse geographies. Finally, implement flexible commercial models-such as reagent rental, subscription-based pricing, or outcome-linked agreements-to address buyer preferences and to share risk with customers during adoption cycles.

Comprehensive mixed-methods research approach combining expert interviews, workflow analysis, regulatory review, and technology assessment to validate diagnostic insights and implications

The research underpinning this analysis employed a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and technical assessment. Primary research included structured interviews with clinicians, laboratory directors, procurement officers, and industry executives to capture real-world diagnostic workflows, purchasing rationales, and unmet needs. Supplemental site visits and workflow mapping provided contextual understanding of specimen handling, result reporting, and integration points for point-of-care and laboratory systems.

Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documentation, and technical product specifications to validate assay performance characteristics and to compare technology platforms. Technology assessments evaluated analytical sensitivity, specificity, turnaround time, throughput, and operational footprint. Regulatory pathways were reviewed across major jurisdictions to identify evidence requirements and approval timelines.

Data triangulation was applied to reconcile discrepancies between primary and secondary sources and to ensure robustness of conclusions. Where available, clinical validation studies and real-world performance data informed assessments of diagnostic utility and suitability for different end-user settings. The methodology also acknowledges limitations, including potential variability in laboratory practices and regional guideline differences, and it emphasizes that insights are intended to support strategic decision-making rather than serve as prescriptive clinical guidance.

Conclusive perspective on the strategic convergence of diagnostic innovation, operational resilience, and clinical stewardship shaping the future of H pylori testing

Diagnostics for Helicobacter pylori are at an inflection point where enhanced molecular capabilities, improved noninvasive tests, and evolving clinical pathways converge to enable more precise patient management. Stakeholders across the ecosystem-manufacturers, laboratories, clinicians, and health systems-must adapt to technological advances while managing supply chain complexities and shifting reimbursement landscapes. Strategic alignment between product design, evidence generation, and end-user needs will be critical to realizing the clinical and commercial potential of next-generation diagnostics.

Looking ahead, success will hinge on the ability to deliver clinically meaningful, operationally sustainable solutions that integrate with care pathways and support antimicrobial stewardship. By prioritizing resilience in sourcing, investing in clinically validated technologies, and engaging payers and providers with clear value propositions, organizations can both improve patient outcomes and secure competitive advantage. The evolving landscape presents significant opportunities for those who combine technical excellence with pragmatic commercialization strategies that respond to regional and end-user heterogeneity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-enhanced endoscopic imaging platforms for real-time Helicobacter pylori detection and diagnostics
  • 5.2. Expansion of point-of-care molecular diagnostic assays for rapid H pylori antibiotic resistance profiling
  • 5.3. Growing adoption of noninvasive 13C-urea breath tests in primary care for early Helicobacter pylori screening
  • 5.4. Development of multiplex serological panels combining Helicobacter pylori virulence factor detection with biomarker profiling
  • 5.5. Emergence of integration between digital health platforms and H pylori diagnostic results for patient management
  • 5.6. Increasing collaborations between diagnostic manufacturers and gastroenterology clinics to streamline H pylori testing workflows
  • 5.7. Regulatory approval trends accelerating next-generation sequencing applications for Helicobacter pylori strain identification
  • 5.8. Rising demand for stool antigen immunoassays in resource-limited settings for accessible Helicobacter pylori diagnosis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Diagnostics Market, by Test Type

  • 8.1. Histology
    • 8.1.1. Hematoxylin And Eosin Staining
    • 8.1.2. Special Stains
  • 8.2. Molecular Test
    • 8.2.1. Isothermal Amplification
    • 8.2.2. Polymerase Chain Reaction
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Rapid Urease Test
    • 8.3.1. Clo Test
    • 8.3.2. PyloriTek Test
  • 8.4. Serology Test
    • 8.4.1. Enzyme Linked Immunosorbent Assay
    • 8.4.2. Lateral Flow Assay
  • 8.5. Stool Antigen Test
    • 8.5.1. Enzyme Immunoassay
    • 8.5.2. Lateral Flow Immunoassay
  • 8.6. Urea Breath Test
    • 8.6.1. 13C Urea Breath Test
    • 8.6.2. 14C Urea Breath Test

9. Helicobacter Pylori Diagnostics Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
      • 9.1.1.1. PCR Kits
      • 9.1.1.2. Rapid Urease Test Kits
      • 9.1.1.3. Serology Test Kits
      • 9.1.1.4. Stool Antigen Test Kits
      • 9.1.1.5. Urea Breath Test Kits
    • 9.1.2. Reagents
    • 9.1.3. Test Strips
  • 9.2. Instruments
    • 9.2.1. Analyzer Equipment
      • 9.2.1.1. Breath Test Analyzers
      • 9.2.1.2. Immunoassay Analyzers
      • 9.2.1.3. PCR Instruments
    • 9.2.2. Endoscopy Systems

10. Helicobacter Pylori Diagnostics Market, by End User

  • 10.1. Ambulatory Care Centers
    • 10.1.1. Community Health Centers
    • 10.1.2. Outpatient Clinics
  • 10.2. Clinics
    • 10.2.1. Primary Care Clinics
    • 10.2.2. Specialty Clinics
  • 10.3. Diagnostic Laboratories
    • 10.3.1. Commercial Laboratories
    • 10.3.2. Reference Laboratories
  • 10.4. Hospitals
    • 10.4.1. Large Hospitals
    • 10.4.2. Small Hospitals

11. Helicobacter Pylori Diagnostics Market, by Technology

  • 11.1. Invasive
    • 11.1.1. Culture
    • 11.1.2. Histology
    • 11.1.3. Rapid Urease Test
  • 11.2. Noninvasive
    • 11.2.1. Antigen Test
    • 11.2.2. Breath Test
      • 11.2.2.1. Stool Antigen Test
      • 11.2.2.2. Urea Breath Test
    • 11.2.3. Molecular
    • 11.2.4. Serology

12. Helicobacter Pylori Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Helicobacter Pylori Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Helicobacter Pylori Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche Ltd
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Danaher Corporation
    • 15.3.4. bioMerieux SA
    • 15.3.5. Thermo Fisher Scientific Inc.
    • 15.3.6. Siemens Healthineers AG
    • 15.3.7. DiaSorin S.p.A.
    • 15.3.8. Bio-Rad Laboratories, Inc.
    • 15.3.9. Fujirebio Inc.
    • 15.3.10. Sekisui Medical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HELICOBACTER PYLORI DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HELICOBACTER PYLORI DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HELICOBACTER PYLORI DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 20